<DOC>
	<DOCNO>NCT01399840</DOCNO>
	<brief_summary>This two-arm , open-label study determine maximum tolerate dose ( MTD ) ass safety , pharmacokinetics , pharmacodynamics , preliminary efficacy BMN 673 patient Acute Myeloid Leukemia ( AML ) , Myelodysplastic Syndrome ( MDS ) , Chronic Lymphocytic Leukemia ( CLL ) Mantle Cell Lymphoma ( MCL ) . Arm 1 enroll patient either AML MDS ; Arm 2 enroll patient either CLL MCL .</brief_summary>
	<brief_title>Study BMN 673 , PARP Inhibitor , Patients With Advanced Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<criteria>1 . 18 year age old . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 3 . Arm 1 AML/MDS : Must available tissue 4 . Arm 2 CLL/MCL : Must available tissue 5 . Have adequate organ function define : 1 . Serum aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) ≤ 2.5 X upper limit normal ( ULN ) ; 2 . Total serum bilirubin ≤ 1.5 X ULN ; 6 . Able take oral medication 7 . Recovered acute toxicity prior treatment 8 . Willing able provide write , sign informed consent nature study explain , prior researchrelated procedure . 9 . If sexually active , must willing use acceptable method contraception therapy 30 day last dose BMN 673 . 10 . If female childbearing potential , must negative serum pregnancy test screen willing additional pregnancy test study . 11 . Willing able comply study procedure . 1 . Acute promyelocytic leukemia , APL [ AML ( 15 ; 17 ) ( q22 ; q12 ) , PMLRARA variant ] . 2 . Diseasespecific exclusion criterion : a. AML : . Marrow cellularity &lt; 25 % ii . Circulating blast &gt; 50,000/mm3 b. MCL CLL : i. Platelet count &lt; 50,000/mm3 ii . Neutrophil count &lt; 1000/mm3 3 . Autologous bone marrow transplant &lt; 6 month Cycle 1 Day 1 4 . Prior allogeneic bone marrow transplant &lt; 6 month Cycle 1 Day 1 and/or presence graft versus host disease ( GVHD ) 5 . Prior treatment : 1 . AML : antileukemia treatment within 14 day Cycle 1 Day 1 ; hydroxyurea treatment within 7 day Cycle 1 Day 1 . 2 . CLL , MCL MDS : antilymphoma/leukemia treatment within 28 day Cycle 1 Day 1 ; 6 . CLL/MCL patient receive transfusion , hematopoietic growth factor within 7 day Cycle 1 Day 1 . 7 . Symptomatic central nervous system ( CNS ) involvement . 8 . Known human immunodeficiency virus ( HIV ) active hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) . 9 . Major surgery within 28 day Cycle 1 , Day 1 . 10 . Active peptic ulcer disease . 11 . Active gastrointestinal tract disease malabsorption syndrome . 12 . Requirement IV alimentation . 13 . Prior surgical procedure affect absorption . 14 . Uncontrolled inflammatory bowel disease ( eg , Crohn 's disease , ulcerative colitis ) . 15 . Myocardial infarction within 6 month Cycle 1 Day 1 , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , unstable angina , unstable cardiac arrhythmia require medication . 16 . Breastfeeding screen plan become pregnant ( self partner ) time study participation . 17 . Use investigational product investigational medical device within 28 day Cycle 1 , Day 1 . 18 . Concurrent disease condition would interfere study participation safety , : 1 . CLL/MCL patient active , clinically significant infection require use parenteral antimicrobial agent , grade &gt; 2 infection NCI CTCAE ( v4.03 ) within 14 day Cycle 1 , Day 1 ( AML/MDS patient control infection eligible study specific time requirement prior Cycle 1 , Day 1 ) ; 2 . Clinically significant bleeding diathesis coagulopathy , include know platelet function disorder ; 3 . Nonhealing wound , ulcer , bone fracture . 19 . Patients receive prior treatment PARP inhibitor eligible Part 2 study ( expansion ) , eligible Part 1 ( dose escalation ) study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>